Heart failure in patients with aortic stenosis: Clinical and prognostic significance of carbohydrate antigen 125 and brain natriuretic peptide measurement

International Journal of Cardiology

Volumn 128, Issue 3, 2008, Pages 406-412

  Antonini Canterin, Francesco ^a   Popescu, Bogdan A ^b   Popescu, Andreea C ^c   Beladan, Carmen C ^b   Korcova, Renata ^a   Piazza, Rita ^a   Cappelletti, Piero ^a   Rubin, Daniela ^a   Cassin, Matteo ^a   Faggiano, Pompilio ^a   Nicolosi, Gian Luigi ^a  

^a S MARIA DEGLI ANGELI HOSPITAL   (Italy)

^b Prof Dr C C Iliescu Institute of Cardiovascular Diseases   (Romania)

^c CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

Aortic stenosis; BNP; Carbohydrate antigen 125; Echocardiography

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; CARBOHYDRATE ANTIGEN;

AGED; AORTA STENOSIS; AORTA VALVE REPLACEMENT; ARTICLE; FEMALE; FOLLOW UP; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; TRANSTHORACIC ECHOCARDIOGRAPHY;

EID: 48149114680     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2007.05.039     Document Type: Article

References (45)

1. Ross Jr. J., and Braunwald E. Aortic stenosis. Circulation 38 Suppl 1 (1968) 61-67
2. Turina J., Hess O., Sepulcri F., and Krayenbuehl H.P. Spontaneous course of aortic valve disease. Eur Heart J 8 (1987) 471-483
3. Bonow R.O., Carabello B.A., de Leon Jr. A.C., et al. ACC/AHA guidelines for the management of patients with valvular heart disease: a report of The American College of Cardiology/American Heart Association Task Force on Practice Guidelines(Committee on Management of Patients with Valvular Heart Disease). J Am Coll Cardiol 32 (1998) 1486-1588
4. Iung B., Gohlke-Barwolf C., Tornos P., et al. Recommendations on the management of the asymptomatic patient with valvular heart disease. Eur Heart J 23 (2002) 1253-1266
5. Rosenhek R., Maurer G., and Baumgartner H. Should early elective surgery be performed in patients with severe but asymptomatic aortic stenosis?. Eur Heart J 23 (2002) 1417-1421
6. Otto C.M., Burwash I.G., Legget M.E., et al. Prospective study of asymptomatic valvular aortic stenosis: clinical, echocardiographic and exercise predictors of outcome. Circulation 95 (1997) 2262-2270
7. Antonini-Canterin F., Huang G., Cervesato E., et al. Relation of the total ejection isovolume index to symptoms in aortic stenosis. Am J Cardiol 90 (2002) 665-668
8. Yasue H., Yoshimura M., Sumida H., et al. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation 90 (1994) 195-203
9. Yamamoto K., Burnett Jr. J.C., Jougasaki M., et al. Superiority of brain natriuretic peptide as a hormonal marker of ventricular systolic and diastolic dysfunction and ventricular hypertrophy. Hypertension 28 (1996) 988-994
10. Prasad N., Bridges A.B., Lang C.C., et al. Brain natriuretic peptide concentrations in patients with aortic stenosis. Am Heart J 133 (1997) 477-479
11. Ikeda T., Matsuda K., Itoh H., et al. Plasma levels of brain and atrial natriuretic peptides elevate in proportion to left ventricular end-systolic wall stress in patients with aortic stenosis. Am Heart J 133 (1997) 307-314
12. Qi W., Mathisen P., Kjekshus J., et al. Natriuretic peptides in patients with aortic stenosis. Am Heart J 142 (2001) 725-732
13. Weber M., Arnold R., Rau M., et al. Relation of N-terminal pro-B-Type natriuretic peptide to severity of valvular aortic stenosis. Am J Cardiol 94 (2004) 740-745
14. Gerber I.L., Stewart R.A., Legget M.E., et al. Increased plasma natriuretic peptides reflect symptom onset in aortic stenosis. Circulation 107 (2003) 1884-1890
15. Gerber I.L., Legget M.E., West T.M., Richards A.M., and Stewart R.A. Usefulness of serial measurement of N-terminal pro-brain natriuretic peptide plasma levels in asymptomatic patients with aortic stenosis to predict symptomatic deterioration. Am J Cardiol 95 (2005) 898-901
16. Bergler-Klein J., Klaar U., Heger M., et al. Natriuretic pepetides predict symptom-free survival and postoperative outcome in severe aortic stenosis. Circulation 109 (2004) 2302-2308
17. Lim P., Monin J.L., Monchi M., et al. Predictors of outcome of patients with severe aortic stenosis and normal left ventricular function: role of B-type natriuretic peptide. Eur Heart J 25 (2004) 2048-2053
18. Watanabe M., Murakami M., Furukawa H., et al. Is measurement of plasma brain natriuretc peptide levels a useful test to detect for surgical timing of valve disease?. Int J Cardiol 96 (2004) 21-24
19. Nagele H., Bahlo M., Klapdor R., Schaeperkoetter D., and Rodiger W. CA125 and its relation to cardiac function. Am Heart J 137 (1999) 1044-1049
20. D'Aloia A., Faggiano P., Aurigemma G., et al. Serum levels of carbohydrate antigen 125 in patients with chronic heart failure. J Am Coll Cardiol 41 (2003) 1805-1811
21. Kouris N.T., Zacharos I.D., Kontogianni D.D., et al. The significance of CA125 levels in patients with chronic congestive heart failure. Correlation with clinical and echocardiographic parameters. Eur J Heart Fail 7 (2005) 199-203
22. Varol E., Ozaydin M., Dogan A., and Kosar F. Tumour marker levels in patients with chronic heart failure. Eur J Heart Fail 7 (2005) 840-843
23. Schiller N.B., Shah P.M., Crawford M., et al. Recommendations for quantification of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantification of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr 2 (1989) 358-367
24. Devereux R.B., Alonso D.R., Lutas E.M., et al. Echocardiographic assessment of left ventricular hypertrophy: comparison with necropsy findings. Am J Cardiol 57 (1986) 450-458
25. Zoghbi W.A., Farmer K.L., Soto J.G., Nelson J.G., and Quinones M.A. Accurate noninvasive quantification of stenotic aortic valve area by Doppler echocardiography. Circulation 73 (1986) 452-459
26. Lubien E., DeMaria A., Krishnaswamy P., et al. Utility of B-natriuretc peptide in detecting diastolic dysfunction: comparison with Doppler velocity recordings. Circulation 105 (2002) 595-601
27. Helmcke F., Nanda N.C., Hsiung M.C., et al. Color Doppler assessment of mitral regurgitation with ortogonal planes. Circulation 75 (1987) 175-183
28. Perry G.J., Helmcke F., Nanda N.C., Byard C., and Soto B. Evaluation of aortic insufficiency by Doppler color flow mapping. J Am Coll Cardiol 9 (1987) 952-959
29. Hein S., Arnon E., Kostin S., et al. Progression from compensated hypertrophy to failure in the pressure-overloaded human heart: structural deterioration and compensatory mechanisms. Circulation 25 (2003) 984-991
30. Nessmith M.G., Fukuta H., Brucks S., and Little W.C. Usefulness of an elevated B-type natriuretic peptide in predicting survival in patients with aortic stenosis treated without surgery. Am J Cardiol 96 (2005) 1445-1448
31. Weber M., Hausen M., Arnold R., et al. The prognostic value of N-terminal pro B-type natriuretic peptide (NT-proBNP) for conservatively and surgically treated patients with aortic valve stenosis. Heart 92 (2006) 1639-1644
32. Neverdal N.O., Knudsen C.W., Husebye T., et al. The effect of aortic valve replacement on plasma B-type natriuretic peptide in patients with severe aortic stenosis - one year follow up. Eur J Heart Fail 8 (2006) 257-262
33. Weber M., Arnold R., Rau M., et al. Relation of N-terminal pro B-type natriuretic peptide to progression of aortic valve disease. Eur Heart J 26 (2005) 1023-1030
34. Ferrari R., Bachetti T., Confortini R., et al. Tumor necrosis factor soluble receptors in patients with various degree of congestive heart failure. Circulation 92 (1995) 1479-1486
35. MacGowan G.A., Mann D.L., Kormos R.L., Feldman A.M., and Murali S. Circulating interleukin-6 in severe heart failure. Am J Cardiol 79 (1997) 1128-1131
36. Zeimet A.G., Offner F.A., Marth C., et al. Modulation of CA125 release by inflammatory cytokines in human peritoneal mesothelial and ovarian cancer cells. Anticancer Res 17 (1997) 3129-3131
37. Faggiano P., D'Aloia A., Brentana L., et al. Serum levels of different tumour markers in patients with chronic heart failure. Eur J Heart Fail 7 (2005) 57-61
38. Bast Jr. R.C., Klug T.L., St John E., et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 309 (1983) 883-887
39. Sjovall K., Nilsson B., and Einhorn N. The significance of serum CA125 in malignant and nonmalignant diseases. Gynecol Oncol 85 (2002) 175-178
40. Bergmann J.F., Bidart J.M., George M., Beaugrand M., Levy V.G., and Bohuon C. Elevation of CA125 in patients with benign and malignant ascites. Cancer 59 (1987) 213-217
41. Sevinc A., Buyukberber S., Sari R., Kiroglu Y., Turk H.M., and Ates M. Elevated serum CA125 in hemodialysis patients with peritoneal, pleural or pericardial fluids. Gynecol Oncol 77 (2000) 254-257
42. Epiney M., Bertussa C., Weil A., Campana A., and Bishof P. CA 125 production by peritoneum: in-vitro and in-vivo studies. Hum Reprod 15 (2000) 1261-1265
43. Gullu I., Yalcin S., and Tekuzman G. Tumour markers in effusions: a comparative study of tumour marker levels in sera and effusion. In: Travis C.C. (Ed). Use of biomarkers in assessing health and environmental impacts of chemical pollutants (1993), Plenum, New York 265-272
44. Duman C., Ercan E., Tengiz I., Bozdemir H., Ercan H.E., and Nalbantgil I. Elevated serum CA 125 levels in mitral stenotic patients with heart failure. Cardiology 100 (2003) 7-10
45. Faggiano P., D'Aloia A., Bignotti T., and Dei Cas L. One biologic marker (carbohydrate antigen-CA125), two different diseases (ovarian cancer and congestive heart failure): practical implications of monitoring CA125 serum levels. A case report. Ital Heart J 4 (2003) 497-499